Entera Bio Current Ratio 2018-2021 | ENTX

Entera Bio current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Entera Bio Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.00B 8.33
2021-03-31 $0.02B $0.01B 1.64
2020-12-31 $0.01B $0.00B 2.78
2020-09-30 $0.01B $0.00B 2.67
2020-06-30 $0.01B $0.00B 2.56
2020-03-31 $0.01B $0.01B 2.84
2019-12-31 $0.02B $0.01B 3.41
2019-09-30 $0.01B $0.00B 2.65
2019-06-30 $0.01B $0.00B 4.51
2019-03-31 $0.01B $0.00B 4.62
2018-12-31 $0.01B $0.00B 3.95
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.01B $0.00B 6.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.101B $0.000B
Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76